I like your plan, but is it the same as Alliacense`s? We really have no clue yet as to how much a patent portfolio license will cost the average company and whether or not a recuring royalty schedule would be pursued. I think it is a good question and not one that is ``out of bounds`` to be asked by shareholders.

Is anyone compiling a joint list of questions to be presented to any or all of the 3 links Mr. Pohl gave in his address?

Further, as far as the ``support page`` questions...do we have anything to support? I got the impression that Ignite and Inflame were not being marketed, but ``could be``. Hope I`m misreading it, or reading to much into it. See below:

Apart from the rights in the Patent Portfolio licensed to P-Newco, Patriot still retains certain rights in the portfolio and complete rights to commercialize our Ignite(TM) and Array products. That business could be another module, either as a division or perhaps as a joint venture with a suitable partner willing to invest in the future of those products.